Lyra Therapeutics Inc (LYRA) - News Archive

In a significant advancement in the treatment landscape for chronic rhinosinusitis (CRS), Lyra Therapeutics, Inc. (Nasdaq: LYRA), a pioneering clinical-stage biotechnology company, has officially announced the full enro...

: Current treatments for chronic rhinosinusitis (CRS) often necessitate systemic administration of anti-inflammatory drugs or invasive surgical interventions. Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage bio...

In an effort to navigate the challenging landscape of the pharmaceutical industry, Lyra Therapeutics, a leading biopharmaceutical company based in Watertown, Massachusetts, has recently announced a series of cost-cuttin...

In an unexpected turn of events, Lyra Therapeutics reported that its Phase 3 ENLIGHTEN 1 Trial for LYR-210 failed to meet its primary endpoint. LYR-210, an innovative therapy for chronic rhinosinusitis, a debilitating c...

In a move highlighting its commitment towards growth and innovation, Lyra Therapeutics, a clinical-stage biotech company focused on developing long-acting, anti-inflammatory sinonasal implants for chronic rhinosinusitis...

These employment inducement awards were approved by Lyras independent directors serving on its Compensation Committee and were granted under the company s 2022 Inducement Award Plan, as amended, and related form of stoc...